TLDR
- ARK Invest bought 359,612 Rocket Lab shares worth about $25.1 million across three ETFs.
- Cathie Wood’s firm also sold 16,422 Alphabet shares worth about $5.8 million.
- ARK now owns more than 3.2 million Rocket Lab shares across its funds, worth roughly $225 million.
- Rocket Lab’s Neutron rocket remains a major part of the growth story, with a debut targeted for late 2026.
- ARK also added several biotech stocks while cutting positions in Twist Bioscience, 10X Genomics and Everpure.
Cathie Wood’s ARK Invest added another $25 million to its Rocket Lab position on Tuesday while trimming its exposure to Alphabet.
ARK bought 359,612 Rocket Lab shares across the ARKK, ARKQ and ARKX ETFs. The purchase was worth about $25.1 million and adds to a position ARK has been building during recent weakness in the stock.
Following the purchase, ARK reportedly owns more than 3.2 million Rocket Lab shares across its ETFs, worth roughly $225 million at recent prices.
ARK Builds Rocket Lab Position
Rocket Lab is best known for Electron, its small-satellite launch vehicle, but much of the longer-term investment case revolves around Neutron.
The larger reusable rocket is designed to compete in the medium-lift launch market. Rocket Lab currently targets a fourth-quarter 2026 debut, although the company has warned that qualification testing could push the launch into 2027.
Rocket Lab is also expanding beyond launch services through satellite systems and communications. Those businesses could give the company broader exposure to the growing commercial and government space markets.
ARK’s latest purchase comes after repeated buying as Rocket Lab shares pulled back from their May highs. The continued accumulation suggests the firm is maintaining its exposure even as the stock begins to recover.
ARK Trims Alphabet
At the same time, ARK sold 16,422 Alphabet shares across ARKQ and ARKX, worth approximately $5.8 million.
The sale is relatively small compared with the Rocket Lab purchase. Alphabet remains one of the world’s largest and most profitable technology companies, but investors continue to debate how artificial intelligence could affect its search business.
Google has also been expanding Gemini and its internally developed AI chips, giving Alphabet additional exposure to the AI infrastructure and software markets.
The contrast highlights two very different investment profiles. Alphabet generates substantial cash flow today, while much of Rocket Lab’s valuation depends on future growth in launch services, Neutron and space infrastructure.
ARK Adds Biotech Exposure
ARK also made several biotechnology trades Tuesday. The firm bought 88,323 shares of Scribe Therapeutics worth about $2.5 million, along with smaller purchases of Veracyte and Beam Therapeutics.
On the selling side, ARK reduced positions in Twist Bioscience and 10X Genomics. It also sold another 19,139 shares of Everpure through ARKW.
The Rocket Lab trade was easily the largest move of the day. It reinforces ARK’s continued focus on disruptive growth themes across space, biotechnology and emerging technologies.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
